September 24, 2024 01:12 PM EDTUpdated 04:07 PM
Pharma
Law

Fed­er­al judge rules against Re­gen­eron's at­tempt to halt Am­gen from launch­ing Eylea biosim­i­lar

Katherine Lewin

News Reporter

Re­gen­eron’s stock $REGN dipped about 4% on Tues­day fol­low­ing a loss in its le­gal bat­tle with Am­gen over com­peti­tors to its block­buster eye treat­ment Eylea …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times